The three types of scaffolds in tissue engineering are natural, synthetic, and composite. Each is defined by the materials used to build it, and each comes with distinct strengths for helping the body regenerate damaged tissue. Natural scaffolds use proteins and sugars found in living organisms. Synthetic scaffolds are built from lab-made polymers. Composite scaffolds combine elements of both to offset the weaknesses of either one alone.
These scaffolds serve as temporary frameworks that guide new cells as they grow, essentially giving the body a structure to rebuild on. To work inside the human body, any scaffold needs to meet a few non-negotiable requirements: it must be biocompatible (not trigger a harmful immune response), biodegradable (break down as new tissue replaces it), and mechanically strong enough to support the tissue it’s meant to regenerate.
Natural Scaffolds
Natural scaffolds are made from materials that already exist in biological systems. The raw ingredients fall into two main groups: proteins like collagen, silk, elastin, and fibrinogen, and polysaccharides (complex sugars) like cellulose, chitin, and chitosan. Because these materials come from living sources, cells tend to recognize and interact with them more readily than they do with lab-made alternatives.
That biological familiarity is the biggest advantage of natural scaffolds. They are biocompatible, biodegradable, and bioactive, meaning they can actively encourage cells to attach, grow, and differentiate into the right tissue type. Researchers have used natural polymer scaffolds in efforts to repair skin, bone, cartilage, nerves, liver, and muscle tissue.
Chitosan, derived from the shells of crustaceans, is one of the most studied natural scaffold materials. It’s non-toxic, biodegradable, and breaks down at a rate that can be tuned by adjusting its chemical structure. In rat studies, chitosan films with a higher degree of deacetylation (84% or above) degraded more slowly and produced a milder inflammatory response in surrounding tissue, while those that broke down quickly triggered more acute inflammation. This illustrates a broader principle: the speed at which a scaffold degrades directly affects how the body reacts to it.
The downside of natural scaffolds is that they tend to be mechanically weaker and harder to manufacture consistently. Batch-to-batch variation is common since the raw materials come from biological sources. They can also degrade unpredictably, which is a problem when you need a scaffold to hold its shape for weeks or months while new tissue forms.
Synthetic Scaffolds
Synthetic scaffolds are built from polymers created in a laboratory, giving engineers precise control over their structure, strength, and degradation rate. The most widely used synthetic scaffold materials include PLA (polylactide), PGA (poly-glycolic acid), PLGA (a copolymer of the two), and PCL (polycaprolactone).
Each polymer breaks down at a different pace, and choosing the right one depends on how long the scaffold needs to last. PGA degrades fast, making it suitable for short-term scaffolds where new tissue forms quickly. PLA degrades slowly and offers moderate mechanical strength, while its more crystalline form is rigid enough for load-bearing applications like bone repair. PCL degrades very slowly and maintains its structural integrity for extended periods, which is useful for bone healing that takes months. PLGA sits in between, with a tunable degradation profile. A 50:50 ratio of its two components breaks down more rapidly, while other ratios last longer, giving designers flexibility based on the specific injury.
The main advantage of synthetic scaffolds is reproducibility. You can manufacture them to exact specifications every time, control their pore size down to the micrometer, and adjust mechanical properties by changing molecular weight or crystallinity. The tradeoff is that synthetic polymers lack the biological signals that natural materials carry. Cells don’t interact with them as naturally, which can mean slower integration with surrounding tissue.
Composite Scaffolds
Composite scaffolds combine natural and synthetic materials, or mix polymers with ceramics, to get the best properties of each. This is the fastest-growing category in scaffold research, and the possible combinations are enormous.
A common strategy pairs a synthetic polymer with a bioceramic. Calcium phosphate ceramics like hydroxyapatite (HA) and tricalcium phosphate (TCP) closely resemble the mineral phase of natural bone, making them excellent at encouraging new bone growth. But ceramics alone are brittle. By embedding them in a flexible polymer matrix, engineers create scaffolds that are both strong and biologically active. In preclinical studies, beta-TCP scaffolds promoted more new bone formation than several other materials tested, and adding components like mesoporous silica-based aerogel to beta-TCP intensified the rate of new bone hardening.
Another approach coats synthetic scaffolds with bioactive materials. PLGA scaffolds coated with a zinc-based silicate ceramic showed the highest bone reconstruction in animal studies, along with enhanced collagen production compared to uncoated PLGA. Calcium silicate scaffolds with a double-layer pore structure achieved roughly 26% new bone formation in the treated area, among the highest percentages reported in preclinical trials.
Composites allow designers to fine-tune nearly every property: how fast the scaffold degrades, how strong it is, how well cells attach to it, and how it interacts with the immune system. That flexibility makes composites the most versatile option, though also the most complex to design and manufacture.
Why Pore Size Matters Across All Three Types
Regardless of material, a scaffold’s physical structure plays a critical role in whether it works. Pore size, the tiny openings throughout the scaffold, determines which cells can migrate in and how they communicate with each other. Pores smaller than 1 micrometer improve cell-surface interaction. Pores between 1 and 3 micrometers enable cell-to-cell communication. Pores of 3 to 12 micrometers allow cells to migrate through the scaffold.
Different tissues demand different pore sizes. Bone and cartilage stem cells differentiate best in pores of 200 to 400 micrometers. Nerve regeneration requires pores around 100 micrometers. Endothelial cells, which line blood vessels, prefer 10 to 25 micrometers. Microvascular cells do best in pores smaller than 38 micrometers. Getting this wrong means cells either can’t enter the scaffold or can’t organize into functional tissue once they do.
How Scaffolds Are Made
Manufacturing methods vary by scaffold type. Porous scaffolds are commonly produced using salt leaching, where salt crystals are mixed into the scaffold material and then dissolved away, leaving behind a network of interconnected pores. Hydrogel scaffolds, which are water-rich and gel-like, are formed by mixing cells with the scaffold material before it solidifies, essentially encapsulating cells within the structure as it sets.
3D bioprinting has dramatically expanded what’s possible. Modern bioprinters can achieve positional accuracy of around 20 micrometers, with some open-source systems reaching approximately 3 micrometers in all three axes. That level of precision lets researchers print scaffolds with complex internal architectures, including perfusable channels that mimic blood vessels, something that was impossible with earlier techniques.
Scaffolds Already in Clinical Use
Scaffold technology has moved beyond the lab. In 2024, the FDA approved Symvess, the first acellular tissue-engineered blood vessel, for use in adults who need emergency restoration of blood flow to a limb after vascular trauma. Symvess is made from human extracellular matrix proteins, the same structural proteins found naturally in blood vessels, and is used when a patient’s own vein isn’t available for grafting. It represents the kind of product that scaffold research has been building toward: an off-the-shelf biological replacement that can be used in urgent clinical situations without needing cells from the patient.